Fig. 3From: Almonertinib-induced interstitial lung disease in a lung adenocarcinoma patient complicated with interstitial lung abnormalitya–c After 22 days of discontinuation of almonertinib, re-examination of chest CT (May 25, 2021) showed interstitial changes in both lungs, especially in the right lower lungBack to article page